Scarica l'app Stockscreener
32.54
2.40%
-0.80
Dopo l'orario di chiusura:
32.75
0.21
+0.65%
Vera Therapeutics Inc Borsa (VERA) Ultime notizie
Vera Therapeutics, Inc. (VERA) Stock Price, News, Quote & History - Yahoo! Finance Canada
VERA Stock Surges After Drug To Treat Rare Kidney Disease Gets FDA Approval – Retail Sees The Move As Catalyst For Vera Therapeutics - Stocktwits
Vera Therapeutics Down Over 8%, On Track for Largest Percent Decrease Since November 2025 -- Data Talk - Moomoo
Vera Therapeutics (NASDAQ: VERA) CEO exercises options and sells shares under preset trading plan - Stock Titan
Vera Therapeutics (VERA) Says TRUTAKNA Met All Phase III Endpoints - finance.yahoo.com
Vera Therapeutics Announces TRUTAKNA Stabilized eGFR and Prevented Kidney Disease Progression through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy - marketscreener.com
Wedbush Maintains Vera Therapeutics(VERA.US) With Hold Rating, Maintains Target Price $34 - Moomoo
Vera Therapeutics Reports Positive Two-Year Phase 3 Trutakna Results - Pulse 2.0
Vera Therapeutics reports strong Phase III tria... - Pluang
VERA: TRUTAKNA's phase III data show strong efficacy and safety, driving rapid U.S. launch momentum - TradingView
Vera Therapeutics: Why I'm Sticking With 'Hold' Despite Today's Positive Trutakna Data - Seeking Alpha
Vera Therapeutics CFO Young Joseph R Exercises 5,000 Stock Options at $3.94 (NASDAQ: VERA) - Kalkine Media
Vera Therapeutics (VERA) Stock Surges Following Promising ORIGIN3 Trial Results - Blockonomi
What's Going on With Vera Therapeutics Stock on Tuesday? - Benzinga
Vera Therapeutics Rises as Investors Focus on TRUTAKNA Launch and Conference Visibility - Quiver Quantitative
Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results - Barron's
Why is Vera Therapeutics stock reversing its premarket gains? - TradingView
TD Cowen reiterates Buy on Vera Therapeutics stock on kidney data - Investing.com
Vera Therapeutics stock maintained at Strong Buy by Raymond James - Investing.com Canada
Vera Therapeutics Announces Positive ORIGIN 3 Trial Outcomes for TRUTAKNA in IgA Nephropathy - Kalkine Media
Vera Therapeutics Shares Rise 13% After TRUTAKNA Meets ORIGIN 3 Trial Endpoints - Yahoo Finance
VERA Stock Jumps 16% Premarket – Trutakna Cuts Kidney Disease Progression Risk By 76%, Full FDA Filing Planned In Q4 - TradingView
Why is Vera Therapeutics stock surging today? - Investing.com
Form 8K Vera Therapeutics Inc For: 15 September By Investing.com - Investing.com Nigeria
Vera Therapeutics Kidney Disease Drug Meets Prespecified Endpoints in Origin 3 Trial - Yahoo Finance
Vera gains on Trutakna late-stage trial win (VERA:NASDAQ) - Seeking Alpha
Vera Therapeutics Announces TRUTAKNA Met All Endpoints in ORIGIN 3 Final Analysis in IgA Nephropathy, with Strong Launch Momentum and Plans for FDA Supplemental BLA Submission - Quiver Quantitative
A kidney treatment kept function steady for two years, Vera says - Stock Titan
Vera Therapeutics (VERA) finance SVP adds 5,000 shares - Stock Titan
Technical Reactions to VERA Trends in Macro Strategies - Stock Traders Daily
Vera Therapeutics at Cantor Fitzgerald conference: launch gains traction By Investing.com - Investing.com Canada
Vera Therapeutics CEO Marshall Fordyce Executes 18,500 Share Sale Under 10b5-1 Trading Plan - Kalkine Media
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Discipline and Rules-Based Execution in VERA Response - Stock Traders Daily
Vera Therapeutics (NASDAQ: VERA) insider to sell tens of thousands of shares - Stock Titan
Vera Therapeutics stock gains after fresh analyst support - ad-hoc-news.de
Vera Therapeutics to Participate at Upcoming Investor Conferences - manilatimes.net
Vera Therapeutics options activity points to institutional bullish call spread on September strikes - Investing.com
Nancy Lee Boman Net Worth (2026) - GuruFocus
Vera Therapeutics (NASDAQ:VERA): What Could Drive the Next Move? - Kalkine Media
What Vera Therapeutics (VERA)'s Widening Losses and Cash Burn Mean For Shareholders - Sahm
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
H.C. Wainwright Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $90 - Moomoo
Bank of America Corp DE Has $23.72 Million Stake in Vera Therapeutics, Inc. $VERA - MarketBeat
Vera Therapeutics upgraded to Buy after FDA nod for TRUTAKNA and positive kidney function data. - Pluang
Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy (NASDAQ:VERA) - Seeking Alpha
Wedbush Reiterates Neutral Rating for Vera Therapeutics (NASDAQ:VERA) - MarketBeat
J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $76 - Moomoo
Vera Therapeutics Stock (VERA) Opinions on Positive eGFR Data Release - Quiver Quantitative
Vera Therapeutics Shares Up 9.7% as $425,000 Drug Launch Puts Focus on Cash Reserves - TechStock²
Vera Therapeutics Climbs as Investors React to TRUTAKNA Launch Progress and Near-Term IgAN Milestones - Quiver Quantitative
Kynam Capital (VERA) now holds 4.01% beneficial stake in Vera Therapeutics - Stock Titan
Vera Therapeutics (NASDAQ:VERA) Shares Gap UpHere's Why - MarketBeat
HC Wainwright Has Positive Estimate for VERA Q3 Earnings - MarketBeat
Vera stock rises on FDA review for kidney drug (VERA:NASDAQ) - Seeking Alpha
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):